EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

被引：81
|
作者：
Ke, E-E [1 ,2 ]
Wu, Yi-Long [1 ,2 ]
机构：
[1] Guangdong Acad Med Sci, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Gen Hosp, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2016年 / 37卷 / 11期
关键词：
GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CIRCULATING TUMOR DNA; PHASE-II TRIAL; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; BRAIN METASTASES; C797S MUTATION; ASIAN PATIENTS;
D O I：
10.1016/j.tips.2016.09.003
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, survival, and quality of life. However, acquired resistance to EGFR-TKIs is inevitable. Ongoing clinical trials will provide evidence for optimal strategies for patients with EGFR mutant non-small-cell lung cancer (NSCLC) in the near future. Numerous new agents are specifically addressing resistance mechanisms; mature data are related to the T790M mutation and MET pathway activation. Here, we provide a comprehensive review of new perspectives on how to optimize the management of this molecular disease.
引用
收藏
页码：887 / 903
页数：17
相关论文
共 50 条
  • [21] ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
    Desai, Aakash
    Vazquez, Tadana A.
    Arce, Keishla M.
    Corassa, Marcelo
    Mack, Philip C.
    Gray, Jhanelle E.
    Pellini, Bruna
    CANCERS, 2024, 16 (05)
  • [22] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [23] Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
    Zhang, Hongye
    Wang, Ruiyu
    Wang, Mingxia
    Luo, Judong
    Liu, Changmin
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 754 - 762
  • [24] Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs
    Matikas, Alexios
    Mistriotis, Dimitrios
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    CLINICAL LUNG CANCER, 2015, 16 (04) : 252 - 261
  • [25] Overcoming therapy resistance in EGFR-mutant lung cancer
    Passaro, Antonio
    Janne, Pasi A.
    Mok, Tony
    Peters, Solange
    NATURE CANCER, 2021, 2 (04) : 377 - 391
  • [26] Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
    Aboubakar Nana, Frank
    Ocak, Sebahat
    PHARMACEUTICS, 2021, 13 (09)
  • [27] ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
    Passaro, A.
    Leighl, N.
    Blackhall, F.
    Popat, S.
    Kerr, K.
    Ahn, M. J.
    Arcila, M. E.
    Arrieta, O.
    Planchard, D.
    de Marinis, F.
    Dingemans, A. M.
    Dziadziuszko, R.
    Faivre-Finn, C.
    Feldman, J.
    Felip, E.
    Curigliano, G.
    Herbst, R.
    Janne, P. A.
    John, T.
    Mitsudomi, T.
    Mok, T.
    Normanno, N.
    Paz-Ares, L.
    Ramalingam, S.
    Sequist, L.
    Vansteenkiste, J.
    Wistuba, I. I.
    Wolf, J.
    Wu, Y. L.
    Yang, S. R.
    Yang, J. C. H.
    Yatabe, Y.
    Pentheroudakis, G.
    Peters, S.
    ANNALS OF ONCOLOGY, 2022, 33 (05) : 466 - 487
  • [28] Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
    Tan, Chee-Seng
    Gilligan, David
    Pacey, Simon
    LANCET ONCOLOGY, 2015, 16 (09) : E447 - E459
  • [29] Targeting the EGFR T790M mutation in non-small-cell lung cancer
    Normanno, Nicola
    Maiello, Monica Rosaria
    Chicchinelli, Nicoletta
    Iannaccone, Alessia
    Esposito, Claudia
    De Cecio, Rossella
    D'alessio, Amelia
    De Luca, Antonella
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (02) : 159 - 165
  • [30] The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
    Lee, Ji Yun
    Ku, Bo Mi
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Kim, Moonjin
    Kim, Sungmin
    Jung, Hyun Ae
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) : 903 - 909
12345